Pluristem Therapeutics Inc (PSTI)

[lorbas95]

Near-term Milestones/Catalysts

Soon: Feedback from BARDA for a project designed to demonstrate the superiority of our PLX-R18 therapy versus current standards of care in the treatment of Acute Radiation Syndrome (ARS).

Q2 (May?): Interim analysis of efficacy (one-year follow-up) for the Phase 3 study in CLI; potential for AA under the EMA's Adaptive Pathways project; full enrollment of study.

May: Possible award by the European Commision for novel regenerative medicines through the RESTORE Consortium, of which Pluristem is a leading member (up to 1b€).

Q3-Q4: Full-enrollment in the Phase 3 study in mucscle recovery; results in Q1-Q2 2021.